ALX Oncology
ALXO
61 hedge funds and large institutions have $51.3M invested in ALX Oncology in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 33 reducing their positions, and 8 closing their positions.
5,288% more call options, than puts
Call options by funds: $431K | Put options by funds: $8K
308% more capital invested
Capital invested by funds: $12.6M → $51.3M (+$38.7M)
0% more funds holding
Funds holding: 61 → 61 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
2.57% less ownership
Funds ownership: 54.45% → 51.89% (-2.6%)
76% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.84M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$689K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$565K |
| 4 |
Two Sigma Investments
New York
|
+$111K |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$79.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.31M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$437K |
| 3 |
Goldman Sachs
New York
|
-$235K |
| 4 |
BlackRock
New York
|
-$233K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$168K |
ALXO Hedge Fund Activity: Q3 2025 in Review
61 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q3 2025, worth a combined $51.3M — up 308% from $12.6M a quarter earlier.
Fund positioning in ALXO was balanced in Q3 2025: 8 funds opened new positions, 8 closed out, 8 added to existing stakes and 33 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.84M. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.31M sold.
- 61 institutional investors held ALX Oncology (ALXO) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $51.3M of ALX Oncology stock for Q3 2025, up 308% quarter-over-quarter.
- 8 funds opened new ALX Oncology positions in Q3 2025 and 8 closed out, a net change of 0 holders.
- The largest ALX Oncology buyer in Q3 2025 was Millennium Management, an estimated $1.84M added.
- The largest ALX Oncology seller in Q3 2025 was Tang Capital Management, an estimated $1.31M sold.
Based on aggregated 13F filings for Q3 2025.